1. Home
  2. ANTA vs ICCC Comparison

ANTA vs ICCC Comparison

Compare ANTA & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Antalpha Platform Holding Company Ordinary Shares

ANTA

Antalpha Platform Holding Company Ordinary Shares

HOLD

Current Price

$3.58

Market Cap

96.5M

Sector

Finance

ML Signal

HOLD

Logo ImmuCell Corporation

ICCC

ImmuCell Corporation

HOLD

Current Price

$10.05

Market Cap

93.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANTA
ICCC
Founded
2022
1982
Country
Singapore
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
96.5M
93.1M
IPO Year
2024
1995

Fundamental Metrics

Financial Performance
Metric
ANTA
ICCC
Price
$3.58
$10.05
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$16.17
N/A
AVG Volume (30 Days)
4.5K
17.8K
Earning Date
06-16-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
53.85
EPS
N/A
0.41
Revenue
N/A
$26,493,169.00
Revenue This Year
$21.95
N/A
Revenue Next Year
$30.46
N/A
P/E Ratio
$19.77
$51.90
Revenue Growth
N/A
51.64
52 Week Low
$3.00
$4.52
52 Week High
$13.82
$12.10

Technical Indicators

Market Signals
Indicator
ANTA
ICCC
Relative Strength Index (RSI) 39.58 37.90
Support Level $3.00 $9.27
Resistance Level $4.17 $10.75
Average True Range (ATR) 0.31 0.45
MACD 0.14 -0.12
Stochastic Oscillator 49.57 22.72

Price Performance

Historical Comparison
ANTA
ICCC

About ANTA Antalpha Platform Holding Company Ordinary Shares

Antalpha Platform Holding Co provides financing, technology and risk management solutions to institutional and corporate customers in the crypto asset industry. The company operates through Antalpha Prime platform in the following areas: Supply chain financing and Technology and services. Its revenue prominently consists of technology financing fees charged on the supply chain loans.

About ICCC ImmuCell Corporation

ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.

Share on Social Networks: